Literature DB >> 27558575

Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.

Julie Waisbren1, Shira Dinner2, Jessica Altman3, Olga Frankfurt4, Irena Helenowski5, Juehua Gao6, Brandon J McMahon2, Brady L Stein2.   

Abstract

Patients with myelodysplastic syndrome (MDS) who present with isolated thrombocytopenia (TCP) constitute a poorly described subgroup. The aim of the present study was to retrospectively evaluate disease characteristics and prognosis in patients with MDS and isolated TCP at a tertiary care center. Fifty patients (12 %) had isolated thrombocytopenia as the first presentation of MDS. Patients had varying MDS sub-classifications and cytogenetic profiles. The most common IPSS-R risk score was low (n = 24), although half of the patients had either IPSS-R intermediate (n = 18), high or very high risk disease (n = 7). Leukemic transformation occurred in 10 patients and there were 14 deaths (28 %) amongst all IPSS-R risk scores. Therapeutic agents used in this patient subgroup included hypomethylating agents and thrombopoietin receptor agonists. Overall, MDS with isolated TCP did not appear to have an inherently indolent course, as has been suggested previously. Future studies are needed to improve risk stratification, identify relevant contributors to disease pathogenesis, and better define treatment modalities.

Entities:  

Keywords:  Acute Myeloid Leukemia; Myelodysplastic syndrome; Myeloid leukemia and dysplasia; Thrombocytopenia; Thrombopoietin analogs

Mesh:

Substances:

Year:  2016        PMID: 27558575     DOI: 10.1007/s12185-016-2081-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  28 in total

Review 1.  Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Anca Prica; Michelle Sholzberg; Rena Buckstein
Journal:  Br J Haematol       Date:  2014-08-26       Impact factor: 6.998

2.  [Myelodysplastic syndrome mimicking idiopathic thrombocytopenic purpura].

Authors:  Yusun Hwang; Jung Won Huh; Yeung Chul Mun; Chu Myong Seong; Wha Soon Chung
Journal:  Korean J Lab Med       Date:  2010-04

3.  [Isolated thrombocytopenia as presenting symptoms of myelodysplastic syndromes].

Authors:  S Mitsutani; T Kohriyama; M Kamio; T Saitoh
Journal:  Rinsho Ketsueki       Date:  1987-06

4.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

5.  Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.

Authors:  Maria Teresa Voso; Susanna Fenu; Roberto Latagliata; Francesco Buccisano; Alfonso Piciocchi; Maria Antonietta Aloe-Spiriti; Massimo Breccia; Marianna Criscuolo; Alessandro Andriani; Stefano Mancini; Pasquale Niscola; Virginia Naso; Carolina Nobile; Anna Lina Piccioni; Mariella D'Andrea; Ada D'Addosio; Giuseppe Leone; Adriano Venditti
Journal:  J Clin Oncol       Date:  2013-06-24       Impact factor: 44.544

6.  Unusual myelodysplastic syndrome with the initial presentation mimicking idiopathic thrombocytopenic purpura.

Authors:  Junya Kuroda; Shinya Kimura; Yutaka Kobayashi; Katsuya Wada; Nobuhiko Uoshima; Toshikazu Yoshikawa
Journal:  Acta Haematol       Date:  2002       Impact factor: 2.195

7.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors:  Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

Review 8.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

9.  Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact.

Authors:  Ulrike Bacher; Torsten Haferlach; Susanne Schnittger; Melanie Zenger; Manja Meggendorfer; Sabine Jeromin; Andreas Roller; Vera Grossmann; Maria-Theresa Krauth; Tamara Alpermann; Wolfgang Kern; Claudia Haferlach
Journal:  Br J Haematol       Date:  2013-12-26       Impact factor: 6.998

Review 10.  Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literature.

Authors:  Juehua Gao; Ryan D Gentzler; Andrew E Timms; Marshall S Horwitz; Olga Frankfurt; Jessica K Altman; LoAnn C Peterson
Journal:  J Hematol Oncol       Date:  2014-04-22       Impact factor: 17.388

View more
  6 in total

1.  Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.

Authors:  Qiu-Sha Huang; Jing-Zhi Wang; Ya-Zhen Qin; Qiao-Zhu Zeng; Qian Jiang; Hao Jiang; Jin Lu; Hui-Xin Liu; Yi Liu; Jing-Bo Wang; Li Su; Hong-Yu Zhang; Zhen-Ling Li; Su-Jun Gao; Bo Huang; Yu-Ying Liu; Yan-Rong Liu; Lan-Ping Xu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Blood Adv       Date:  2019-11-12

2.  Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand.

Authors:  Philip Yi Choi; Eileen Merriman; Ashwini Bennett; Anoop K Enjeti; Chee Wee Tan; Isaac Goncalves; Danny Hsu; Robert Bird
Journal:  Med J Aust       Date:  2021-10-10       Impact factor: 12.776

Review 3.  Extracellular Vesicles in Haematological Disorders: A Friend or a Foe?

Authors:  Ioanna Lazana
Journal:  Int J Mol Sci       Date:  2022-09-04       Impact factor: 6.208

4.  GPX3 methylation is associated with hematologic improvement in low-risk myelodysplastic syndrome patients treated with Pai-Neng-Da.

Authors:  Shujun Yang; Tong Gao; Zhonghua Zheng; Binbin Lai; Lixia Sheng; Zhijuan Xu; Xiao Yan; Jiaping Wang; Shiwei Duan; Guifang Ouyang
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

Review 5.  When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis.

Authors:  Nicolas Bonadies; Alicia Rovó; Naomi Porret; Ulrike Bacher
Journal:  J Clin Med       Date:  2021-03-02       Impact factor: 4.241

6.  Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients.

Authors:  Judith Strapatsas; Elena Calina Barbulescu; Michael Lauseker; Jennifer Kaivers; Barbara Hildebrandt; Kathrin Nachtkamp; Corinna Strupp; Martina Rudelius; Rainer Haas; Ulrich Germing
Journal:  Ann Hematol       Date:  2021-07-29       Impact factor: 3.673

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.